Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol mebutate vs cryotherapy for actinic keratoses and field cancerization
2015-005820-24Phase 4Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Jun 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of ingenol mebutate in actinic keratosis (AK) and cutaneous field cancerization (CFC) (2 arms), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: At least 75% reduction in total AK count relative to baseline. Started Jun 2021; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)cutaneous field cancerization (CFC)
Beyond the preview
Go deeper on 2015-005820-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005820-24.